Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Issue 6 (11th September 2018)

• Record Type: Journal Article
• Authors: Ziegler, David; Wong, Marie; Mayoh, Chelsea; Kumar, Amit; Tsoli, Maria; Mould, Emily; Tyrrell, Vanessa; Khuong-Quang, Dong-Anh; Pinese, Mark; Gayevskiy, Velimir; Cohn, Richard; Lau, Loretta; Reynolds, Mark; Cox, Michael; Gifford, Andrew; Rodriguez, Michael; Cowley, Mark; Ekert, Paul; Marshall, Glenn; Haber, Michelle
• Is Part Of: British journal of cancer. Volume 119:Issue 6(2018)
• Page Start: 693
• Page End: 696
• Publication Date: 2018-09-11
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; Tumors -- Periodicals; 616.994
• DOI: 10.1038/s41416-018-0251-2
• Languages: English
• ISSNs: 0007-0920

Abstract

Abstract Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical role in tumourigenesis in 40% of infant HGG. Here we report the first case of a TRK fusion-driven HGG treated with larotrectinib—the first selective pan-TRK inhibitor in clinical development. This 3-year-old girl had failed multiple therapies including chemotherapy and radiotherapy. Tumour profiling confirmed anETV6–NTRK3 fusion. Treatment with larotrectinib led to rapid clinical improvement with near total resolution of primary and metastatic lesions on MRI imaging. This is the first report of a TRK fusion glioma successfully treated with a TRK inhibitor.